ATE419252T1 - Antagonisten des a2b-adenosinrezeptors - Google Patents
Antagonisten des a2b-adenosinrezeptorsInfo
- Publication number
- ATE419252T1 ATE419252T1 AT04810023T AT04810023T ATE419252T1 AT E419252 T1 ATE419252 T1 AT E419252T1 AT 04810023 T AT04810023 T AT 04810023T AT 04810023 T AT04810023 T AT 04810023T AT E419252 T1 ATE419252 T1 AT E419252T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- optionally substituted
- disorders
- sub
- substituted heteroaryl
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51601903P | 2003-10-31 | 2003-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE419252T1 true ATE419252T1 (de) | 2009-01-15 |
Family
ID=34549473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04810023T ATE419252T1 (de) | 2003-10-31 | 2004-10-26 | Antagonisten des a2b-adenosinrezeptors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7449473B2 (enExample) |
| EP (1) | EP1678181B1 (enExample) |
| JP (1) | JP4863876B2 (enExample) |
| KR (1) | KR20060111467A (enExample) |
| CN (1) | CN1890241A (enExample) |
| AT (1) | ATE419252T1 (enExample) |
| AU (1) | AU2004285013A1 (enExample) |
| BR (1) | BRPI0415888A (enExample) |
| CA (1) | CA2544193C (enExample) |
| DE (1) | DE602004018808D1 (enExample) |
| ES (1) | ES2318363T3 (enExample) |
| MX (1) | MXPA06004789A (enExample) |
| WO (1) | WO2005042534A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| ES2387653T3 (es) * | 2004-09-01 | 2012-09-27 | Gilead Sciences, Inc. | Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B |
| MX2007004373A (es) | 2004-10-15 | 2007-08-08 | Cv Therapeutics Inc | Metodo para prevenir y tratar el remoldeo de las vias respiratorias e inflamacion pulmonar utilizando antagonistas de receptor adenosina a2b. |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| EP2301937A1 (en) * | 2005-06-16 | 2011-03-30 | Cv Therapeutics, Inc. | Prodrugs of A2b adenosine receptor antagonists |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| EP1989210A2 (en) * | 2006-03-02 | 2008-11-12 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| EP2029603A1 (en) * | 2006-06-05 | 2009-03-04 | Astra Zeneca AB | Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
| US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
| GB0718434D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| TW200938200A (en) * | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
| CA2718983C (en) | 2008-03-26 | 2015-12-08 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
| WO2010009194A1 (en) * | 2008-07-16 | 2010-01-21 | King Pharmaceuticals Research And Development, Inc. | Methods of treating atherosclerosis |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| EP2405917B1 (en) | 2009-03-13 | 2014-04-23 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| US8815858B2 (en) * | 2010-05-21 | 2014-08-26 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
| CN103261200B (zh) | 2010-09-13 | 2016-03-30 | 阿迪维纳斯疗法有限公司 | 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途 |
| CA2862263C (en) | 2011-12-27 | 2016-09-06 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| PT4122926T (pt) * | 2021-04-14 | 2025-07-29 | Shionogi & Co | Derivados de triazina com atividade inibitória da replicação de vírus e composição farmacêutica que compreende os mesmos |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| WO2001094350A1 (en) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
| NZ532816A (en) | 2001-11-09 | 2005-11-25 | Cv Therapeutics Inc | A2B adenosine receptor antagonists |
-
2004
- 2004-10-26 WO PCT/US2004/035453 patent/WO2005042534A2/en not_active Ceased
- 2004-10-26 JP JP2006538172A patent/JP4863876B2/ja not_active Expired - Lifetime
- 2004-10-26 BR BRPI0415888-1A patent/BRPI0415888A/pt not_active Application Discontinuation
- 2004-10-26 AT AT04810023T patent/ATE419252T1/de not_active IP Right Cessation
- 2004-10-26 EP EP04810023A patent/EP1678181B1/en not_active Expired - Lifetime
- 2004-10-26 CA CA2544193A patent/CA2544193C/en not_active Expired - Lifetime
- 2004-10-26 MX MXPA06004789A patent/MXPA06004789A/es unknown
- 2004-10-26 DE DE602004018808T patent/DE602004018808D1/de not_active Expired - Lifetime
- 2004-10-26 AU AU2004285013A patent/AU2004285013A1/en not_active Abandoned
- 2004-10-26 ES ES04810023T patent/ES2318363T3/es not_active Expired - Lifetime
- 2004-10-26 KR KR1020067008426A patent/KR20060111467A/ko not_active Withdrawn
- 2004-10-26 CN CNA200480031969XA patent/CN1890241A/zh active Pending
- 2004-10-26 US US10/973,167 patent/US7449473B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP4863876B2 (ja) | 2012-01-25 |
| WO2005042534A3 (en) | 2005-08-25 |
| CA2544193C (en) | 2012-03-27 |
| MXPA06004789A (es) | 2006-07-03 |
| CN1890241A (zh) | 2007-01-03 |
| KR20060111467A (ko) | 2006-10-27 |
| US7449473B2 (en) | 2008-11-11 |
| EP1678181A2 (en) | 2006-07-12 |
| ES2318363T3 (es) | 2009-05-01 |
| CA2544193A1 (en) | 2005-05-12 |
| AU2004285013A1 (en) | 2005-05-12 |
| US20050119287A1 (en) | 2005-06-02 |
| EP1678181B1 (en) | 2008-12-31 |
| DE602004018808D1 (de) | 2009-02-12 |
| JP2007509947A (ja) | 2007-04-19 |
| WO2005042534A2 (en) | 2005-05-12 |
| BRPI0415888A (pt) | 2007-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE419252T1 (de) | Antagonisten des a2b-adenosinrezeptors | |
| ATE520694T1 (de) | A2b-adenosinrezeptorantagonisten | |
| JP5670912B2 (ja) | ｐ３８ＭＡＰキナーゼ阻害剤 | |
| EP2350047A2 (en) | P38 map kinase inhibitors | |
| JP2005531584A5 (enExample) | ||
| JP2006514110A (ja) | Ｉｐ受容体アンタゴニストとしてのフェニルまたはヘテロアリールアミノアルカン誘導体 | |
| EA200500777A1 (ru) | Производные 3-(3,5-диоксо-4,5-дигидро-3h-(1,2,4)триазин-2-ил)бензамида в качестве ингибиторов p2xдля лечения воспалительных заболеваний | |
| WO2010038086A2 (en) | Novel compounds | |
| WO2009029998A1 (en) | Retrometabolic compounds | |
| CA2540163A1 (en) | Thrombin receptor antagonists | |
| JP2004217668A (ja) | インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプｉｖと腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用 | |
| EP2556068A1 (en) | P38 map kinase inhibitors | |
| JP2008525453A5 (enExample) | ||
| EP3144303B1 (en) | 6-substituted phenoxychroman carboxylic acid derivatives | |
| JP2008543860A5 (enExample) | ||
| JP2007509947A5 (enExample) | ||
| ES2291630T3 (es) | Nuevos compuestos. | |
| WO2005035501A1 (ja) | 新規オレフィン誘導体 | |
| JPH01313469A (ja) | キナゾリン、その製法及びこれを含有する抗腫瘍作用を有する製薬学的組成物 | |
| WO2006016237A3 (en) | Heterocyclic derivatives as anti-inflammatory agents | |
| WO2008071665A1 (en) | A nicotinamide derivative useful as p38 kinase inhibitor | |
| ES2360123T3 (es) | Derivados de amida. | |
| HK1235780B (en) | 6-substituted phenoxychroman carboxylic acid derivatives | |
| TH87151A (th) | สารประกอบเคมี |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |